1. Home
  2. PETS vs BTAI Comparison

PETS vs BTAI Comparison

Compare PETS & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PetMed Express Inc.

PETS

PetMed Express Inc.

HOLD

Current Price

$1.85

Market Cap

38.0M

ML Signal

HOLD

Logo BioXcel Therapeutics Inc.

BTAI

BioXcel Therapeutics Inc.

HOLD

Current Price

$1.14

Market Cap

35.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PETS
BTAI
Founded
1996
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Retail-Drug Stores and Proprietary Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
38.0M
35.8M
IPO Year
2003
2018

Fundamental Metrics

Financial Performance
Metric
PETS
BTAI
Price
$1.85
$1.14
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$23.00
AVG Volume (30 Days)
195.7K
636.3K
Earning Date
06-09-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
75.63
EPS
N/A
N/A
Revenue
$273,800,000.00
N/A
Revenue This Year
N/A
$197.82
Revenue Next Year
$2.98
$910.15
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.57
$1.01
52 Week High
$4.10
$8.08

Technical Indicators

Market Signals
Indicator
PETS
BTAI
Relative Strength Index (RSI) 38.13 49.65
Support Level $1.62 $1.05
Resistance Level $2.41 $1.26
Average True Range (ATR) 0.13 0.09
MACD -0.02 -0.01
Stochastic Oscillator 33.56 30.14

Price Performance

Historical Comparison
PETS
BTAI

About PETS PetMed Express Inc.

PetMed Express Inc is a nationwide direct-to-consumer pet pharmacy and online provider of prescription and non-prescription medications, foods, supplements, supplies, and vet services for dogs, cats, and horses. It markets and sells directly to consumers through its websites, toll-free numbers, and mobile application, offering convenience, price, speed of delivery, and customer service. It provides access to branded pharmaceuticals, generic medications, compounded prescription medications, over-the-counter health and wellness products, prescription and non-prescription food, pharmacy fulfillment, and AutoShip capabilities. Its digital platform offers pet healthcare solutions for chronic conditions, including allergies, arthritis, anxiety, kidney-related conditions, and hyperthyroidism.

About BTAI BioXcel Therapeutics Inc.

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

Share on Social Networks: